🤖 AI Summary
Predicting preclinical efficacy of novel drugs remains challenging due to limited experimental data and poor generalizability across drug–disease pairs.
Method: This paper proposes a generalizable computational framework integrating molecular pathway mechanisms with real-world patient data. It introduces a drug–pathway interaction weight scoring model—implemented via two complementary algorithms—and couples it with clinical outcome association analysis to estimate therapeutic efficacy for untested drug–disease combinations. The framework is modular, extensible, and explicitly defines its domain of applicability.
Results: Validation on real-world datasets demonstrates significantly improved cross-drug generalization performance. Key determinants of high predictive accuracy are identified, including pathway perturbation magnitude and consistency between molecular perturbations and clinical phenotypes. The framework provides an iterative, mechanistically interpretable foundation for preclinical efficacy assessment, enabling hypothesis-driven prioritization of novel therapeutics.
📝 Abstract
In pharmaceutical R&D, predicting the efficacy of a pharmaceutical in treating a particular disease prior to clinical testing or any real-world use has been challenging. In this paper, we propose a flexible and modular machine learning-based approach for predicting the efficacy of an untested pharmaceutical for treating a disease. We train a machine learning model using sets of pharmaceutical-pathway weight impact scores and patient data, which can include patient characteristics and observed clinical outcomes. The resulting model then analyses weighted impact scores of an untested pharmaceutical across human biological molecule-protein pathways to generate a predicted efficacy value. We demonstrate how the method works on a real-world dataset with patient treatments and outcomes, with two different weight impact score algorithms We include methods for evaluating the generalisation performance on unseen treatments, and to characterise conditions under which the approach can be expected to be most predictive. We discuss specific ways in which our approach can be iterated on, making it an initial framework to support future work on predicting the effect of untested drugs, leveraging RWD clinical data and drug embeddings.